Sitemap | Feedback

Advanced search

Journal of Case Reports

Interstitial Lung Disease as Presenting Feature of SLE

symbicort generic equivalent

symbicort dosage

augmentin sciroppo

augmentin compresse driverblog.suddath.com

Sumantro Mondal, Tony Ete, Debanjali Sinha, Atanu Chakraborty, Arijit Nag, Soumik Sarkar, Jyotirmoy Pal, Alakendu Ghosh

From the Department of Medicine, Institute of Post Graduate Medical Education and Research, Kolkata, India.

Corresponding Author:
Dr. Sumantro Mondal Email: drmsumantro@gmail.com

Received: 07-NOV-2013

Accepted: 05-FEB-2014

Published Online: 05-MAR-2014

DOI:	http://dx.doi.org/10.17659/01.2014.0021

Abstract

Interstitial lung disease (ILD) has been considered as an unusual pulmonary manifestation of systemic lupus erythematosus. Patients of ILD usually present with progressive dry cough and exertional dyspnea. ILD is usually seen in long standing SLE patients and follows a chronic course. ILD as the initial manifestation of SLE is very rare. Our middle aged female patient presented with pulmonary symptoms, renal impairment and arthralgia. She was finally diagnosed as having SLE by relevant autoantibody profile and renal biopsy along with HRCT proven ILD.

Keywords :

Lupus erythematosus, Systemic, Lung diseases, Interstitial, Dyspnea, Cough, Arthalgia.

Article Options

FULL TEXT
ABSTRACT
PDF

PRINTER FRIENDLY VERSION

Search PubMed for

Search Google Scholar for

Article Statistics

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

Last updated on Dec 04, 2024